Welcome to our dedicated page for Trulieve Cannabis SEC filings (Ticker: TCNNF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Trulieve Cannabis Corp. filings document the regulatory record of a British Columbia cannabis issuer operating as a vertically integrated multi-state operator in the U.S. Recent Form 8-K reports cover operating results, Regulation FD presentations, material definitive agreements, executive compensation matters, and board or officer transitions.
Proxy filings describe annual meeting matters, director elections, executive compensation, equity awards, and shareholder governance. Debt-related filings disclose senior secured notes due 2030, indenture terms, subsidiary guarantees, and related capital-structure obligations tied to Trulieve and its restricted subsidiaries.
Trulieve Cannabis Corp. reoriented its structure in the first half of 2026 by completing a Deconsolidation Transaction on June 3, 2026, in which mixed-use cannabis subsidiary Harvest was deconsolidated and retained as a 90% equity method investment. This triggered a largely non‑cash loss of $403.333 million and drove a Q2 net loss of $406.062 million, compared with a small loss a year earlier. Q2 2026 revenue declined about 10% to $270.952 million, though gross margin remained near 60%.
After the transaction Trulieve operates exclusively in medical cannabis markets across four states, with 206 dispensaries and 10 cultivation/processing sites, and holds a $152.503 million equity method stake in Harvest plus a management services agreement generating fee revenue. Cash and cash equivalents increased to $325.420 million as of June 30, 2026, supported by $108.847 million of operating cash flow in the first six months, while long‑term funding includes $200.000 million of 10.50% 2030 private placement notes and $94.551 million of other notes payable. Federal rescheduling of medical cannabis to Schedule III led the company to compute 2026 taxes without applying IRC Section 280E to medical operations, lowering its effective tax rate even as legacy uncertain tax position liabilities remain high at $598.187 million.
Trulieve Cannabis reported second-quarter 2026 revenue of $271 million, down 10% from a year earlier, with 94% from retail and medical-only revenue of $222 million. Gross profit was $162 million, a 60% margin.
GAAP net loss attributable to common shareholders was $406 million or $(2.10) per share, driven by a $403.3 million loss on deconsolidating its mixed medical and adult-use Harvest operations, which were restructured to enable listing on the NYSE. Adjusted net income was $20.4 million ($0.11 per share) and adjusted EBITDA $98 million, a 36% margin. Cash flow from operations reached $108.8 million year-to-date, free cash flow $74.4 million, and cash was $325.4 million against $289 million of debt at 9.6% interest.
Following federal rescheduling of state-licensed medical marijuana to Schedule III, Trulieve registered all medical facilities with the DEA, now operates 207 DEA-registered medical dispensaries and 3.5 million square feet of capacity, and retains a 90% economic interest in Harvest. The company also authorized a share repurchase program up to the lesser of $50 million or 8,495,038 subordinate voting shares and now expects at least $225 million of 2026 operating cash flow and up to $95 million of 2026 capital expenditures.
Trulieve Cannabis Corp. reported the results of a special meeting of shareholders held on August 5, 2026. Shareholders were asked to vote on a proposal regarding Delaware domestication of the company and on a separate adjournment proposal, both of which had been described in a definitive proxy statement filed on June 25, 2026.
The Delaware domestication proposal received 71,756,586 votes for, 383,078 votes against, and 50,472 abstentions. The adjournment proposal received 71,718,977 votes for, 358,779 votes against, and 112,380 abstentions.
Trulieve Cannabis Corp. ownership update: AdvisorShares Trust reports beneficial ownership of 10,641,152 subordinate voting shares, representing 6.26% of the class as of 06/30/2026. The filing shows sole voting and dispositive power over those shares.
Trulieve Cannabis Corp. reported a leadership change in its finance organization. As of June 30, 2026, the company eliminated the stand-alone role of Chief Accounting Officer and terminated Brett Walsh’s employment in that position without cause.
At the same time, Trulieve designated its Chief Financial Officer, Jan Reese, as principal accounting officer, consolidating the top finance and accounting responsibilities under one executive. The company noted that Reese will not receive any change or increase in compensation for assuming the additional accounting officer duties.
Trulieve Cannabis Corp. Chairman and CEO Kim A. Rivers reported an open-market sale of 136,811 Subordinate Voting Shares at a weighted average price of $8.756 per share. After this sale, she directly holds 1,476,913 Subordinate Voting Shares.
The sale was effected under a Rule 10b5-1 plan to sell 2.5 million shares that she adopted on March 16, 2026. A first tranche of 1,699,007 Subordinate Voting Shares under this plan has been completed, and she has notified the administering broker-dealer of her intention to terminate the plan on August 11, 2026 before any additional sales.
Rivers also has exposure through Multiple Voting Shares that are convertible into Subordinate Voting Shares on a one-for-100 basis, including holdings reported directly and indirectly via Traunch IV LLC, for which she disclaims beneficial ownership except to the extent of her pecuniary interest.
Trulieve Cannabis Corp. Chairman and CEO Kim A. Rivers reported open-market sales of 1,080,000 Subordinate Voting Shares. She sold 380,000 shares at a weighted average price of $8.469 per share, 400,000 shares at $8.169 per share, and 300,000 shares also at $8.169 per share.
These sales were made under a Rule 10b5-1 plan adopted on March 16, 2026 to sell approximately 2.5 million shares, with a first tranche of 1,699,007 shares covered by a Form 144 filed on June 17, 2026. After these transactions, Rivers directly holds 1,613,724 Subordinate Voting Shares.
She also holds Multiple Voting Shares convertible into 15,166,700 Subordinate Voting Shares directly, and an additional 986,700 underlying Subordinate Voting Shares are held indirectly through Traunch IV LLC, where she may be deemed to exercise voting and investment control but disclaims beneficial ownership except for her pecuniary interest.
Trulieve Cannabis Corp. is asking shareholders to approve a Delaware Domestication, moving its corporate home from British Columbia to Delaware through a court-approved plan of arrangement. The change would keep each investor’s ownership percentage the same, converting existing Subordinate and Multiple Voting Shares into equivalent Delaware classes.
Management argues Delaware better matches Trulieve’s U.S.-based operations, U.S. legal and accounting framework, and NYSE listing, and could improve market acceptance and access to capital. The meeting will be held virtually on August 5, 2026, also seeking authority to adjourn if more time is needed to gather votes.
Trulieve Cannabis Corp. Chairman and CEO Kim A. Rivers reported open-market sales of 482,196 Subordinate Voting Shares. These sales occurred on June 17, 18 and 22, 2026 at weighted average prices around $9.35–$9.46 per share under transaction code S.
The filing notes these transactions were effected pursuant to a Rule 10b5-1 plan to sell 2.5 million shares adopted on March 16, 2026, with a Form 144 covering a first tranche of 1,699,007 Subordinate Voting Shares filed on June 17, 2026. Following the reported sales, Rivers directly holds 2,693,724 Subordinate Voting Shares.
She also has Multiple Voting Shares convertible into 15,166,700 Subordinate Voting Shares directly and 986,700 Subordinate Voting Shares indirectly through Traunch IV LLC, as disclosed in the derivative holdings and related footnotes.
Wilson Davis submitted a Form 144 notice relating to proposed sales of Subordinate Voting Shares of Trulieve Cannabis Corp. The filing lists multiple grant dates and share lots tied to RSU award agreements and a merger agreement, including several specific share amounts and dates.
The excerpt shows RSU-related lots such as 19,700 shares (12/29/2022), 44,354 shares (12/29/2023), 1,439,662 shares (09/17/2024), and others; additional lots include 59,301, 19,765, 98,289, and 17,936 with their respective award dates. The filer is identified at an address in Salt Lake City and the exchange listed is NYSE.